Byakika-Kibwika, PaulineAchan, JaneLamorde, MohammedKarera-Gonahasa, CarineKiragga, Agnes N.Mayanja-Kizza, HarrietKiwanuka, NoahNsobya, SamTalisuna, Ambrose O.Merry, Concepta2022-01-122022-01-122017Byakika-Kibwika, P., Achan, J., Lamorde, M., Karera-Gonahasa, C., Kiragga, A. N., Mayanja-Kizza, H., ... & Merry, C. (2017). Intravenous artesunate plus Artemisnin based Combination Therapy (ACT) or intravenous quinine plus ACT for treatment of severe malaria in Ugandan children: a randomized controlled clinical trial. BMC infectious diseases, 17(1), 1-9. DOI 10.1186/s12879-017-2924-510.1186/s12879-017-2924-5https://nru.uncst.go.ug/xmlui/handle/123456789/1222Severe malaria is a medical emergency associated with high mortality. Adequate treatment requires initial parenteral therapy for fast parasite clearance followed by longer acting oral antimalarial drugs for cure and prevention of recrudescence. In a randomized controlled clinical trial, we evaluated the 42-day parasitological outcomes of severe malaria treatment with intravenous artesunate (AS) or intravenous quinine (QNN) followed by oral arteenArtesunateQuinineArtemisinin combination therapySevere malariaRe-infectionArticle